These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27135484)

  • 1. The Roles of Cathelicidin LL-37 in Inflammatory Bowel Disease.
    Sun L; Wang W; Xiao W; Yang H
    Inflamm Bowel Dis; 2016 Aug; 22(8):1986-91. PubMed ID: 27135484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases.
    Schauber J; Rieger D; Weiler F; Wehkamp J; Eck M; Fellermann K; Scheppach W; Gallo RL; Stange EF
    Eur J Gastroenterol Hepatol; 2006 Jun; 18(6):615-21. PubMed ID: 16702850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating cathelicidin levels correlate with mucosal disease activity in ulcerative colitis, risk of intestinal stricture in Crohn's disease, and clinical prognosis in inflammatory bowel disease.
    Tran DH; Wang J; Ha C; Ho W; Mattai SA; Oikonomopoulos A; Weiss G; Lacey P; Cheng M; Shieh C; Mussatto CC; Ho S; Hommes D; Koon HW
    BMC Gastroenterol; 2017 May; 17(1):63. PubMed ID: 28494754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATF4 Deficiency Promotes Intestinal Inflammation in Mice by Reducing Uptake of Glutamine and Expression of Antimicrobial Peptides.
    Hu X; Deng J; Yu T; Chen S; Ge Y; Zhou Z; Guo Y; Ying H; Zhai Q; Chen Y; Yuan F; Niu Y; Shu W; Chen H; Ma C; Liu Z; Guo F
    Gastroenterology; 2019 Mar; 156(4):1098-1111. PubMed ID: 30452920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of human cathelicidin peptide LL-37 in inflammatory bowel disease.
    Kusaka S; Nishida A; Takahashi K; Bamba S; Yasui H; Kawahara M; Inatomi O; Sugimoto M; Andoh A
    Clin Exp Immunol; 2018 Jan; 191(1):96-106. PubMed ID: 28872665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging roles of the host defense peptide LL-37 in human cancer and its potential therapeutic applications.
    Wu WK; Wang G; Coffelt SB; Betancourt AM; Lee CW; Fan D; Wu K; Yu J; Sung JJ; Cho CH
    Int J Cancer; 2010 Oct; 127(8):1741-7. PubMed ID: 20521250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical localization of vascular endothelial growth factor in colonic mucosa of patients with inflammatory bowel disease.
    Griga T; May B; Pfisterer O; Müller KM; Brasch F
    Hepatogastroenterology; 2002; 49(43):116-23. PubMed ID: 11941933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The roles of cathelicidin LL-37 in immune defences and novel clinical applications.
    Nijnik A; Hancock RE
    Curr Opin Hematol; 2009 Jan; 16(1):41-7. PubMed ID: 19068548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-inflammatory and antibacterial effects of human cathelicidin active fragment KR-12 in the mouse models of colitis: a novel potential therapy of inflammatory bowel diseases.
    Fabisiak N; Fabisiak A; Chmielowiec-Korzeniowska A; Tymczyna L; Kamysz W; Kordek R; Bauer M; Kamysz E; Fichna J
    Pharmacol Rep; 2021 Feb; 73(1):163-171. PubMed ID: 33219923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unique features of human cathelicidin LL-37.
    Bandurska K; Berdowska A; Barczyńska-Felusiak R; Krupa P
    Biofactors; 2015; 41(5):289-300. PubMed ID: 26434733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-quality 3D structures shine light on antibacterial, anti-biofilm and antiviral activities of human cathelicidin LL-37 and its fragments.
    Wang G; Mishra B; Epand RF; Epand RM
    Biochim Biophys Acta; 2014 Sep; 1838(9):2160-72. PubMed ID: 24463069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease.
    Wehkamp J; Fellermann K; Herrlinger KR; Baxmann S; Schmidt K; Schwind B; Duchrow M; Wohlschläger C; Feller AC; Stange EF
    Eur J Gastroenterol Hepatol; 2002 Jul; 14(7):745-52. PubMed ID: 12169983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The human cathelicidin hCAP18/LL-37: a multifunctional peptide involved in mycobacterial infections.
    Méndez-Samperio P
    Peptides; 2010 Sep; 31(9):1791-8. PubMed ID: 20600427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MUC2 Mucin and Butyrate Contribute to the Synthesis of the Antimicrobial Peptide Cathelicidin in Response to Entamoeba histolytica- and Dextran Sodium Sulfate-Induced Colitis.
    Cobo ER; Kissoon-Singh V; Moreau F; Holani R; Chadee K
    Infect Immun; 2017 Mar; 85(3):. PubMed ID: 28069814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial and chemoattractant activity, lipopolysaccharide neutralization, cytotoxicity, and inhibition by serum of analogs of human cathelicidin LL-37.
    Ciornei CD; Sigurdardóttir T; Schmidtchen A; Bodelsson M
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2845-50. PubMed ID: 15980359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell differentiation is a key determinant of cathelicidin LL-37/human cationic antimicrobial protein 18 expression by human colon epithelium.
    Hase K; Eckmann L; Leopard JD; Varki N; Kagnoff MF
    Infect Immun; 2002 Feb; 70(2):953-63. PubMed ID: 11796631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease.
    Reinecker HC; Steffen M; Witthoeft T; Pflueger I; Schreiber S; MacDermott RP; Raedler A
    Clin Exp Immunol; 1993 Oct; 94(1):174-81. PubMed ID: 8403503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of cathelicidins in the innate host defenses of mammals.
    Zanetti M
    Curr Issues Mol Biol; 2005 Jul; 7(2):179-96. PubMed ID: 16053249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease.
    Louis E; Ribbens C; Godon A; Franchimont D; De Groote D; Hardy N; Boniver J; Belaiche J; Malaise M
    Clin Exp Immunol; 2000 May; 120(2):241-6. PubMed ID: 10792371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new transcription factor that regulates TNF-alpha gene expression, LITAF, is increased in intestinal tissues from patients with CD and UC.
    Stucchi A; Reed K; O'Brien M; Cerda S; Andrews C; Gower A; Bushell K; Amar S; Leeman S; Becker J
    Inflamm Bowel Dis; 2006 Jul; 12(7):581-7. PubMed ID: 16804395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.